Pathogenesis of diabetic macro- and microangiopathy

Clinical Nephrology

Volumn 70, Issue 1, 2008, Pages 1-9

  Gartner V ^a   Eigentler, T K ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

AGE products; Angiotensin 2; Antherosclerosis; CRP; Diabetes mellitus; Diabetic nephropathy; Insulin resistance; Interleukin 6; Oxidative stress

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; C REACTIVE PROTEIN; COLLAGEN TYPE 4; COLLAGEN TYPE 6; FIBRONECTIN; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 6; LAMININ; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ARTERIAL WALL THICKNESS; ARTERIOSCLEROSIS; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CELL PROLIFERATION; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC MACROANGIOPATHY; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DYSLIPIDEMIA; ELECTRON MICROSCOPY; ENDOTHELIUM LESION; ENZYME ACTIVITY; FOAM CELL; GLOMERULONEPHRITIS; GLOMERULOSCLEROSIS; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY BLOOD FLOW; KIDNEY FAILURE; KIDNEY FIBROSIS; LYMPHOCYTE ACTIVATION; MACROPHAGE MIGRATION; OBESITY; PATHOGENESIS; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; SMOOTH MUSCLE FIBER;

EID: 47549089706     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp70001     Document Type: Review

References (62)

1. 1-mediated induction of peritubular myofibroblasts. Kidney Int. 2002; 61: 2066-2077.
2. Bak M, Thomsen K, Christiansen T, Flyvbjerg A. Renal enlargement precedes renal hyperfiltration in early experimental diabetes in rats. J Am Soc Nephrol. 2000; 11: 1287-1292.
3. Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, Tracy RP. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes. 2001; 50: 2384-2389.
4. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002; 287: 2570-2581.
5. Bohle A, Mackensen-Haen S, von Gise H, Grund KE, Wehrmann M, Bats C, Bogenschütz O, Schmitt H, Nagy J, Müller C. The consequences of tubulo-interstitial changes for renal function in glomerulopathies. A morphometric and cytological analysis. Pathol Res Pract. 1990; 186: 135-144.
6. Bohlender JM, Franke S, Stein G, Wolf G. Advanced glycation end products and the kidney. Am J Physiol Ren Physiol. 2005; 289: F645-F659.
7. Brewster UC, Perazella MA. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med. 2004; 116: 263-272.
8. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001; 414: 813-820.
9. Camejo G, Olsson U, Hurt-Camejo E, Baharamian N, Bondjers G. The extracellular matrix on atherogenesis and diabetes-associated vascular disease. Atherosclerosis. 2002; Suppl 3: 3-9.
10. Cameron JS. The discovery of diabetic nephropathy: from small print to centre stage. J Nephrol. 2006; 19 (Suppl 10): S75-S87.
11. Castoldi G, Galimberti S, Riva C, Papagna R, Querci F, Casati M, Zerbini G, Caccianiga G, Ferrarese C, Baldoni M, Valsecchi MG, Stella A. Association between serum values of C-reactive protein and cytokine production in whole blood of patients with Type 2 diabetes. Clin Sci (Lond). 2007; 113: 103-108.
12. Chen S, Jim B, Ziyadeh FN. Diabetic nephropathy and transforming growth factor-β: transforming our view of glomerulosclerosis and fibrosis build-up. Semin Nephrol. 2003; 23: 532-543.
13. Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, de Cesare D, De Blasis G, Muraro R, Bei R, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation. 2003; 108: 1070-1077.
14. Clinton SK, Libby P. Cytokines and growth factors in atherogenesis. Arch Pathol Lab Med. 1992; 116: 1292-1300.
15. Dandona P, Aljada A, Chaudhuri A, Mohanty P. Endothelial dysfunction, inflammation and diabetes. Rev Endocrinol Metab Disord. 2004; 5: 189-197.
16. Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens. 2007; 21: 20-27.
17. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004; 350: 1387-1397.
18. de Rekeneire N, Peila R, Ding J, Colbert LH, Visser M, Shorr RI, Kritchevsky SB, Kuller LH, Strotmeyer ES, Schwartz AV, Vellas B, Harris TB. Diabetes, hyperglycemia, and inflammation in older individuals: the health, aging and body composition study. Diabetes Care. 2006; 29: 1902-1908.
19. Drumm K, Gassner B, Silbernagl S, Gekle M. 2001 Albumin in the mg/ l range activates NF-κB in renal proximal tubule-derived cell lines via tyrosine kinases and protein kinase C. Eur J Med Res. 2001; 6: 247-258.
20. Ferri C, Desideri G, Valenti M, Bellini C, Pasin M, Santucci A, De Mattia G. Early upregulation of endothelial adhesion molecules in obese hypertensive men. Hypertension. 1999; 34: 568-573.
21. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000; 102: 42-47.
22. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of Type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002; 51: 1131-1137.
23. Ford ES. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care. 1999; 22: 1971-1977.
24. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, O'Reilly DS, Packard CJ, Sattar N. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes. 2002; 51: 1596-1600.
25. Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med. 2002; 195: 245-257.
26. Gokden N, Cetin N, Colakoglu N, Kumar J, Abul-Ezz S, Barlogie B, Liapis H, Walker PD. Morphologic manifestations of combined light-chain deposition disease and light-chain cast nephropathy. Ultrastruct Pathol. 2007; 31: 141-149.
27. Hoshi S, Shu Y, Yoshida F, Inagaki T, Sonoda J, Watanabe T, Nomoto K, Nagata M. Podocyte injury promotes progressive nephropathy in zucker diabetic fatty rats. Lab Invest. 2002; 82: 25-35.
28. Iwasaki T, Nakajima A, Yoneda M, Terauchi Y. Relationship between the serum concentrations of C-reactive protein and parameters of adiposity and insulin resistance in patients with Type 2 diabetes mellitus. Endocr J. 2006; 53: 345-356.
29. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest. 1995; 95: 2111-2119.
30. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995 - 2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998; 21: 1414-1431.
31. Leake DS, Rankin SM. The oxidative modification of low-density lipoproteins by macrophages. Biochem J. 1990; 270: 741-748.
32. Li JJ, Kwak SJ, Jung DS, Kim JJ, Yoo TH, Ryu DR, Han SH, Choi HY, Lee JE, Moon SJ, Kim DK, Han DS, Kang SW. Podocyte biology in diabetic nephropathy. Kidney Int. 2007; Suppl: S36-S42.
33. Liang CP, Han S, Senokuchi T, Tall AR. The macrophage at the crossroads of insulin resistance and atherosclerosis. Circ Res. 2007; 100: 1546-1555.
34. Maier V. Koronararteriensklerose bei Diabetikern und Nichtdiabetikern mit und ohne Raucheranamnese: Eine vergleichende histologisch-immunhistologische Untersuchung mit klinisch-morphologischer Korrelation. Tübingen: Dissertation; 2007.
35. Mezzano S, Droguett A, Burgos ME, Ardiles LG, Flores CA, Aros CA, Caorsi I, Vio CP, Ruiz-Ortega M, Egido J. Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy. Kidney Int. 2003; Suppl: S64-S70.
36. Minamino T, Miyauchi H, Yoshida T, Ishida Y, Yoshida H, Komuro I. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation. 2002; 105: 1541-1544.
37. Moller DE, Kaufman KD. Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med. 2005; 56: 45-62.
38. Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, Yoshida T, Imaizumi T. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with Type 2 diabetes. Mol Med. 2007; 13: 185-189.
39. Nangaku M. Mechanisms of tubulointerstitial injury in the kidney: final common pathways to end-stage renal failure. Intern Med. 2004; 43: 9-17.
40. Nicholas SB. Advances in pathogenetic mechanisms of diabetic nephropathy. Cell Mol Biol (Noisy-le-grand). 2003; 49: 1319-1325.
41. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, Coplon NS, Sun L, Meyer TW. Podocyte loss and progressive glomerular injury in Type II diabetes. J Clin Invest. 1997; 99: 342-348.
42. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing Type 2 diabetes mellitus. JAMA. 2001; 286: 327-334.
43. Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-κB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol. 2000; 20: 645-651.
44. Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in Type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis. 1999; 34: 795-808.
45. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999; 340: 115-126.
46. Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA. The expression of TNF alpha by human muscle. Relationship to insulin resistance. J Clin Invest. 1996; 97: 1111-1116.
47. Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, Nussberger J, Harringer W, Drexler H. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation. 2000; 101: 1372-1378.
48. Schleicher E, Friess U. Oxidative stress, AGE, and atherosclerosis. Kidney Int. 2007; Suppl: S17-S26.
49. Serri O, Renier G. Intervention in diabetic vascular disease by modulation of growth factors. Metabolism. 1995; 44: 83-90.
50. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007; 132: 2169-2180.
51. Strawn WB, Ferrario CM. Mechanisms linking angiotensin II and atherogenesis. Curr Opin Lipidol. 2002; 13: 505-512.
52. Sun H, Koike T, Ichikawa T, Hatakeyama K, Shiomi M, Zhang B, Kitajima S, Morimoto M, Watanabe T, Asada Y, Chen YE, Fan J. C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance. Am J Pathol. 2005; 167: 1139-1148.
53. Tabuchi M, Inoue K, Usui-Kataoka H, Kobayashi K, Teramoto M, Takasugi K, Shikata K, Yamamura M, Ando K, Nishida K, Kasahara J, Kume N, Lopez LR, Mitsudo K, Nobuyoshi M, Yasuda T, Kita T, Makino H, Matsuura E. The association of C-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis. J Lipid Res. 2007; 48: 768-781.
54. Tamada S, Asai T, Kuwabara N, Iwai T, Uchida J, Teramoto K, Kaneda N, Yukimura T, Komiya T, Nakatani T, Miura K. Molecular mechanisms and therapeutic strategies of chronic renal injury: the role of nuclear factor κB activation in the development of renal fibrosis. J Pharmacol Sci. 2006; 100: 17-21.
55. Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, Pischetsrieder M, Stern D, Schmidt AM, D'Agati VD. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol. 2000; 11: 1656-1666.
56. Torzewski J, Torzewski M, Bowyer DE, Frohlich M, Koenig W, Waltenberger J, Fitzsimmons C, Hombach V. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol. 1998; 18: 1386-1392.
57. Tsalamandris C, Allen TJ, Gilbert RE, Sinha A, Pagiotopoulos S, Cooper ME, Jerums G. Progressive decline in renal function in diabetic patients with and without albuminuria. Diabetes. 1994; 43: 649-655.
58. van der Woude FJ, van Det NF. Heparan sulphate proteoglycans and diabetic nephropathy. Exp Nephrol. 1997; 5: 180-188.
59. Verma S, Kuliszewski MA, Li SH, Szmitko PE, Zucco L, Wang CH, Badiwala MV, Mickle DA, Weisel RD, Fedak PW, Stewart DJ, Kutryk MJ. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation. 2004; 109: 2058-2067.
60. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003; 112: 1796-1808.
61. Wolf G, Ziyadeh FN. The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms. Am J Kidney Dis. 1997; 29: 153-163.
62. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol. 2001; 158: 1039-1051.